Amendment Tool

v1.5 25 Mar 2021

For office use QC: No

	MAPS-2										
Short project title*:											
IRAS project ID* (or REC reference if no IRAS project ID is available):											
Sponsor amendment reference number*:	MA_01_21										
Sponsor amendment date* (enter as DD/MM/YY):	30 November 2021										
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment will IRAS submission; the change of PI at Adde	e removal of NHS s	sites that are not a								
		•	Specific study	,							
Project type (select):			ue bank	k							
, , , ,			Research data								
Has the study been reviewed by a UKECA-recognised Re	coarch Ethios		- Nesearch date	I							
Committee (REC) prior to this amendment?:	Search Ethics	•	Yes	(O No						
What type of UKECA-recognised Research Ethics Commit		NHS/HSC RE	:C								
is applicable? (select):		Ministry of Defence (MoDREC)									
Is all or part of this amendment being resubmitted to the R Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?		() Yes	(No						
Where is the NHS/HSC Research Ethics Committee (REC	England	Wales	Scotland	Northern Irelar							
the study based?:		•	0	0	0						
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	Yes O No									
EudraCT number*:		2021-003853-40									
Was this clinical trial of an investigational medicinal processed under the Combined Ways of Working (C)	O Yes ● No										
Did the study receive Pharmacy Assurance?:			O Yes	No							
Was the study a clinical investigation or other study of a m does the amendment make it one?:	edical device OR) Yes	(No						
Did the study involve the administration of radioactive substrequiring ARSAC review, OR does the amendment introdu	(No									
Did the study involve the use of research exposures to ion (not involving the administration of radioactive substances; amendment introduce this?:		Yes	(O No							
Did the study have Radiation Assurance OR is Radiation being sought for the first time because of this amendme		O Yes	No								
Did the study involve adults lacking capacity OR does the introduce this?:		() Yes	O No							
Did the study involve access to confidential patient informatirect care team without consent OR does the amendment	() Yes	(No							
Did the study involve prisoners OR does the amendment in) Yes	No								
Did the study involve children OR does the amendment int	() Yes	No								
Did the study involve NHS/HSC organisations prior to this		Yes	○ No								
Did the study involve non-NHS/HSC organisations OR doe introduce them?:	es the amendment	() Yes	No							
		England	Wales	Scotland	Northern Irelar						
Lead nation for the study:		•	0	0	0						
Which nations had participating NHS/HSC organisations p amendment?	rior to this	V	V	V	7						
unchanone.											

Section 2: Summary of change(s)

What do you want to update?:	Project information New site/PI only										
Please note: Each change being made as part of the amen- nvestigational medicinal product (CTIMP) involves an update information documents to be given to participants, these sho is available on the "Glossary of Amendment Options" tab. To	e to the Investigator's Brould be entered into the a	ochure (IB), affection mendment tool as	ng the Reference S three separate cha	Safety Information	(RSI) and so the						
	Change 1										
Area of change (select)*:	Participating Organis	sations									
Specific change (select - only available when area of change is selected first)*:	Addition of sites unde	dertaking the same activities as existing sites									
Further information (free text - note that this field will adapt to the amount of text entered):	The following NHS h Liverpool University I Aravind Manoj), Broa Pl: Dr. Aravind Mano Warwickshire NHS T Hospitals NHS Found Tees and Hartlepool Hospital (City Hospita Surrey Hospital (Surr Victoria Hospital (Bel Sandwell General Ho Ispoglou), and Fairfie Narayanamoorthi Sa Dr. Nasar Ahmad), S	Hospital (Liverpool dgreen Hospital (Li)), University Hosp rust; Pl: Dr. Usmar dation Trust; Pl: Dr. Hospitals NHS Fotals Sunderland NH ey and Sussex Hefast - Belfast Health (Sandwell ar idl General Hospitar ravanan), New Cro	University Hospital Liverpool University ital Coventry (University ital Coventry (University ital Coventry (University ital Coventry (University ital Coventry italian) Hospital (Pennine Acute Hoss Hospital (he Rose	Is NHS Foundation I Hospitals NHS Fersity Hospitals C Royal Infirmary (E Idan), North Tees Dr. Ijaz Anwar), S t; Pl. Dr. Naweed t; Pl. Dr. Giosue (Trust; Pl. Carolee M Hospitals NHS Hospitals NHS Tr Liyal Wolverhampt	on Trust; PI: Dr. coundation Trust; coventry and Bradford Teaching Hospital (North Gunderland Royal Sattar), East Gulli), Royal McLaughlin), Trust; PI: Dr. Sissi ist; PI: Dr. on NHS Trust; PI:						
Applicability:		England	Wales	Scotland	Northern Ireland						
Where are the participating NHS/HSC organisations locate	ed that will be affected	V		V	V						
by this change?*: Will all participating NHS/HSC organisations be affected b some? (please note that this answer may affect the categorians):		() All	○ Some Add another change: ✓							
	Change 2										
Area of change (select)*:	Researchers										
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or tempo	orary arrangements	s to cover the abse	nce of a PI							
Further information (free text - note that this field will adapt to the amount of text entered):	Dr.Kayvan Khadjooi Addenbrookes Hospi		riti Agrawal and be	come the new PI	at Cambridge,						
Applicability:		England	Wales	Scotland	Northern Ireland						
Where are the participating NHS/HSC organisations locat by this change?*:	ed that will be affected	V									
Will all participating NHS/HSC organisations be affected b some? (please note that this answer may affect the categorange):		(P All		O Some						
				Add another cha	ange: 🗸						
	Change 3										
Area of change (select)*:	1	ations									
	Tarticipating Organis	articipating Organisations									
Specific change (select - only available when area of change is selected first)*:	Early closure or without	drawal of research	sites								
Further information (free text - note that this field will adapt to the amount of text entered):	The following sites need to be removed from MAPS-2 as they can no longer participate: NHS Forth Valley, Yeovil District Hospital, Peterborough City Hospital, Basildon University Hospital, Frimley Health NHS Foundation Trust, University Hospital of Wales, The Royal Surrey NHS Foundation Trust, Norfolk & Norwich University Hospital, Worthing Hospital.										
Applicability:		England	Wales	Scotland	Northern Ireland						
Where are the participating NHS/HSC organisations located by this change?*:		Ø	V	V							
Will all participating NHS/HSC organisations be affected b some? (please note that this answer may affect the categ change):		(A II		O Some						
				Add another cha	ange:						

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Angela Shone
Email address*:	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

Please note: This section is for infor			. Dotta		1110 000	J. 1011 11	0011	ipioto	aatom	atioaii	, buoc	u on t	no opt	10110 0	010010	u III 00	Jouonic	, i dile	, <u>.</u> .
	Review bodies																		
	UK wide:				England and Wales:			Scotland:			Northern Ireland:								
		npetent Authority RA - Medicines	ompetent Authority HRA - Devices	ARSAC	Radiation Assurance	3W Governance	C (MCA)	(1)	HMPPS	A and HCRW Approval	S (AWIA)	do	(RAEC)	National coordinating function	REC	C Data Guardians	Prisons	National coordinating function	
	REC	Comp MHR/	Compe	ARS	Rad	UKSW	REC	CAG	HMF	HRA	REC	PBPP	SPS	Nati	HSC	HSC	Pris	Nati	Category:
Change 1:						(Y)				(Y)				(Y)				(Y)	New site
Change 2:						(Y)				(Y)				N				N	Α
Change 3:						(Y)				(Y)				(Y)				N	Α
Overall reviews for the amendme	nt:																		
Full review:						N				N				N				N	
Notification only:						Υ				Υ				Υ				Υ	
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	Α																		